Cybin Inc. plans a $150M private placement for its FDA-designated breakthrough therapy, CYB003, for major depressive disorder.

Cybin Inc. plans a $150M private placement for its psychedelic-based treatment, CYB003, which gained a breakthrough therapy designation from the FDA. The treatment aims to help major depressive disorder patients. The private placement will be led by Deep Track Capital, with participation from RA Capital Management, Avidity Partners, Acorn Bioventures, Altium Capital, Logos Capital, Octagon Capital, and other institutional investors.

March 13, 2024
6 Articles

Further Reading